Resources and Education for Operationalizing Bispecifics

Author(s):

Ryan Haumschild, PharmD, MS, MBA,Issam S. Hamadeh, PharmD, BCPS, BCOP

Key Takeaways

Institutions can utilize specialized training programs and partnerships with biotech firms to address bispecific antibody challenges.
Comprehensive regulatory guidance is crucial for navigating the complex approval processes associated with bispecific antibodies.
Stakeholders need education on the unique pharmacodynamics and clinical implementation of bispecific antibodies.
Strategies for managing potential adverse effects are essential for successful integration into treatment protocols.

Panelists discuss how infrastructure including specialized staff training, updated protocols, enhanced monitoring systems, and comprehensive educational resources for health care providers is essential for institutions to successfully implement and optimize bispecific antibody therapies while ensuring patient safety and treatment efficacy.

EP: 1.Current Landscape of Bispecific Therapies for RRMM

EP: 2.Operationalizing Bispecific Therapy and the Impact of CAR-T Advancements on Sequencing

EP: 3.Best Practices for Standardizing Step-Up Dosing

EP: 4.Dosing Frequency and Formulary Decisions for Bispecific Antibodies

Now Viewing

EP: 5.Resources and Education for Operationalizing Bispecifics

EP: 6.Safety Profiles of Bispecific Antibodies for RRMM

EP: 7.Preventing CRS and ICANS Across Sites of Care

EP: 8.Managing CRS and ICANS: Approaches and Protocols

EP: 9.Infection Prevention and Leveraging EHR for Bispecific Therapy Management

EP: 10.Navigating REMS Requirements and Educating Other Stakeholders on Bispecific Therapies

EP: 11.Administering Bispecifics in the Community vs Academic Centers

EP: 12.Improving Transitions of Care for Patients Receiving Bispecific Therapies and Final Recommendations

Video content above is prompted by the following

What resources can institutions looking to provide bispecific antibodies utilize to overcome these challenges discussed thus far?
What further education and information would be helpful for stakeholders regarding operationalizing bispecific antibodies?